ZEOX Zeo ScientifiX, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1557376 · Fiscal year ends 06/30
Financial factors as of 2025-10-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY12.5%
TTM net income YoY-17.3%
TTM EPS YoY-16.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin82.1%
Operating margin-103.6%
Net margin-106.2%
FCF margin-14.3%
EBITDA margin-102.2%
Returns
ROE—
ROA-348.3%
ROIC (approx.)—
Asset turnover3.28x
Leverage & solvency
Liabilities / assets193.2%
Debt / equity—
Current ratio0.33x
Interest coverage-54.96x
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-303.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242025-10-31 | FY20242024-10-31 | FY20232023-10-31 | FY20222022-10-31 | FY20212021-10-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.20M | $4.62M | $4.56M | $6.49M | $5.60M |
| Cost of revenue | $931,000 | $844,000 | $508,000 | $753,534 | $547,881 |
| Gross profit | $4.27M | $3.78M | $4.05M | $5.74M | $5.05M |
| R&D expense | $100,000 | $164,000 | $922,700 | $791,300 | $1.12M |
| SG&A expense | $9.65M | $9.10M | $10.82M | $14.58M | $17.79M |
| Operating income | -$5.39M | -$5.32M | -$6.77M | -$8.84M | -$12.74M |
| Interest expense | $98,000 | $92,000 | $431,000 | $398,260 | $37,934 |
| Pretax income | — | — | — | -$8.90M | -$12.76M |
| Income tax | — | — | — | — | $0 |
| Net income | -$5.52M | -$4.71M | -$6.99M | -$8.90M | -$12.76M |
| EBITDA | -$5.31M | -$5.25M | -$6.28M | -$8.51M | -$12.69M |
| EPS (basic) | -0.86 | -0.74 | -0.99 | -1.56 | -0.01 |
| EPS (diluted) | -0.86 | -0.74 | -0.99 | -1.56 | -0.01 |
| Weighted avg. shares (diluted) | 6.41M | 6.34M | 7.03M | 5.69M | 1.06B |
| Banking | |||||
| Net interest income | — | — | — | — | -$37,934 |
| Balance sheet | |||||
| Cash & equivalents | $221,000 | $657,000 | $1.76M | $3.75M | $108,570 |
| Receivables | $35,000 | $194,000 | $18,000 | $55,110 | $104,150 |
| Inventory | $423,000 | $232,000 | $310,000 | $248,510 | $234,827 |
| Current assets | $958,000 | $1.17M | $2.20M | $4.37M | $517,194 |
| PP&E, net | $569,000 | $478,000 | $573,000 | $1.68M | $1.11M |
| Total assets | $1.53M | $1.64M | $2.78M | $6.20M | $1.93M |
| Current liabilities | $2.87M | $3.29M | $4.01M | $4.06M | $4.13M |
| Short-term debt | $243,000 | $680,000 | $657,000 | $563,111 | $140,434 |
| Long-term debt | — | — | $68,000 | — | — |
| Total debt | — | — | $725,000 | — | — |
| Total liabilities | $2.95M | $3.30M | $4.02M | $4.31M | $4.60M |
| Shareholders' equity | -$1.42M | -$1.65M | -$1.24M | $1.89M | -$2.67M |
| Net debt | — | — | -$1.03M | — | — |
| Shares outstanding | 6.75M | 6.34M | 7.28M | 7.40M | 1.13B |
| Cash flow statement | |||||
| Operating cash flow | -$718,000 | -$1.45M | -$2.20M | -$3.17M | -$2.68M |
| Capital expenditure | $23,000 | — | $26,000 | $824,743 | $424,742 |
| Free cash flow | -$741,000 | — | -$2.22M | -$3.99M | -$3.11M |
| Investing cash flow | -$23,000 | -$45,000 | $615,000 | -$824,743 | -$424,742 |
| Financing cash flow | $305,000 | $396,000 | -$415,000 | $7.64M | $2.62M |
| Depreciation & amortization | $73,000 | $74,000 | $486,000 | $332,508 | $52,702 |
| Stock-based compensation | $4.69M | $3.85M | $3.21M | $3.92M | $8.65M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.